Heart failure (HF) is a complex clinical syndrome with multiple interactions between the failing myocardium and cerebral (dys-)functions. Bi-directional feedback interactions between the heart and the brain are inherent in the pathophysiology of HF: (i) the impaired cardiac function affects cerebral structure and functional capacity, and (ii) neuronal signals impact on the cardiovascular continuum. These interactions contribute to the symptomatic presentation of HF patients and affect many co-morbidities of HF. Moreover, neuro-cardiac feedback signals significantly promote aggravation and further progression of HF and are causal in the poor prognosis of HF. The diversity and complexity of heart and brain interactions make it difficult to develop a comprehensive overview. In this paper a systematic approach is proposed to develop a comprehensive atlas of related conditions, signals and disease mechanisms of the interactions between the heart and the brain in HF. The proposed taxonomy is based on pathophysiological principles. Impaired perfusion of the brain may represent one major category, with acute (cardio-embolic) or chronic (haemodynamic failure) low perfusion being sub-categories with mostly different consequences (i.e. ischaemic stroke or cognitive impairment, respectively). Further categories include impairment of higher cortical function (mood, cognition),
Introduction
Heart failure (HF) is a complex clinical syndrome that involves all organs and systems in the body and is particularly prevalent in the elderly presenting with multiple co-morbidities. In patients aged over 75 years, 90% have at least two, and 83% have at least three concurrent disease conditions requiring active management. 1 The associated co-morbidities play important roles in the progression of HF, hospitalizations, and outcome. Besides aggravation of the HF syndrome, they account for additional treatments, increased disease burden and health care costs of HF. Brain disorders, however defined, form a group of HF-related co-morbidities that are both common and very difficult to manage.
The interaction between the heart and the brain is particularly important as the two organ systems share many pathophysiological mechanisms ( Table 1) . Both organs are affected by common cardiovascular risk factors including hypertension, diabetes and dyslipidaemia, and both are victims of ischaemic insult due to atherosclerotic and thrombotic processes, leading to acute damage and/or chronic organ dysfunction. The heart and the brain are linked by multiple feedback signals that account for mutual interaction, aggravation and progression of disease processes. Indirect and direct interactions between both organs led to the concept of a 'cardio-cerebral syndrome' in HF. 2 Although being important co-morbidities, interactions between heart and brain function such as ischaemic stroke, depression, and cognitive impairment are inadequately addressed in HF practice guidelines and proven therapeutic options are lacking or largely empirical. More work is warranted to unravel the complex interaction between vegetative and higher cortical functions on one side and the haemodynamic implications arising from the failing heart on the other side. Addressing more thoroughly the co-morbidities of HF is a major challenge in the clinical workup of patients and a priority task for the Heart Failure Association (HFA). To this effect the Study Group on Heart and Brain Interaction in HF has been established by the HFA. This review results from a workshop of the study group that was held in November 2015 in Berlin and from subsequent work within the study group. The aim is to summarize current knowledge on the wider range of heart and brain mutual influences, functional interactions and clinical implications. A systematic order of pathophysiological principles, feedback signals and categories of functional impairment is conceptualized.
. 
A systematic approach to heart and brain interactions in heart failure
Multiple signals, pathologies and functional interactions link the failing heart with a plethora of regulatory and higher cortical functions. A comprehensive overview of these interactions is crucial for a deeper understanding of the pathogenetic background and optimal management of HF patients. To promote and integrate further research in this field, this systematic concept may be helpful to develop a comprehensive atlas of related conditions, signals and disease mechanisms.
The bi-directional concept of the failing heart affecting cerebral function and of neuronal signals impacting on the myocardium is understood as the underlying principle of such taxonomy. Direct signals between the heart and the brain such as low cortical and brain stem perfusion, and those with indirect impact such as peripheral muscle reflex circuits need to be distinguished, and feedback mechanisms that promote disease progression vs. mere phenotypic clinical signs should be categorized. A systematic concept addressing those categories is proposed in Table 2 and Figure 1 .
A. Impaired cerebral perfusion
Stroke in patients with heart failure Prevalence, incidence and risk factors for ischaemic stroke in heart failure Stroke is the most common cause of disability in adult life and a major cause of death in developed countries. 3, 4 A strong interaction between HF and ischaemic stroke is well established, which in turn substantially contributes to morbidity and mortality in HF patients. 5 HF induces a state of hypercoagulability through a number of mechanisms: decreased blood flow velocity with rheological alterations, increased aggregation of thrombocytes, reduced fibrinolysis, endothelial dysfunction, inflammatory activation and malfunctioning of cerebral autoregulation are factors contributing to the risk of thromboembolism related to HF. Besides the high risk of embolus formation due to impaired rheology, patients with HF are at increased risk for ischaemic stroke due to concomitant factors such as small-vessel occlusion and large artery atherosclerosis, which are common in ischaemic HF. (supplementary material online, Table S1 ). In stroke patients with HF, the recurrence rate of stroke is increased about two-fold and risk of death is increased more than two-fold compared to stroke patients without HF. 6, 7 In patients with carotid artery stenosis, further reduced perfusion pressure may result in greater volume of ischaemic lesion if patients have systolic HF. 8 Notably, after the first 12 months of stroke the main cause of mortality is cardiovascular events rather than (recurrent) stroke itself. 9 Studies in HF patients with reduced ejection fraction (HFrEF) as well as those with preserved ejection fraction (HFpEF) have shown higher rates of stroke and systemic embolic events as compared to the general population. The prevalence of stroke does not differ between HF patients with preserved and reduced ejection fraction and ranges between 7-10% in various trials (supplementary material online, Table S2 ). A cerebral lesion may manifest as ischaemic stroke but also may remain clinically undetected as a so-called 'silent infarction'. The prevalence of silent cerebral infarctions is comparably high in HF cohorts ranging between 20-40%, 10 which is two to four-fold higher than in age-matched subjects without HF. 'Silent strokes', however, are not truly 'silent', but have been linked to cognitive function and dementia.
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In the population-based Framingham Heart Study, the relative risk of stroke in individuals with HF was 4.1 for men and 2.8 for women compared to those without HF. 12 The risk of stroke in the presence of atrial fibrillation (AF), which is found in 5-50% of HF patients depending on the clinical severity of HF, 13 is enhanced two to three-fold compared to HF patients without AF (supplementary material online, Table S3 ). Numerous observational case-control studies and/or registries report wide variations in the incidence of systemic emboli, ranging from 1.4% to 12.5% in HF patients including those with AF and those receiving oral anticoagulation therapy.
14 In post-hoc analyses of major HFrEF trials including SAVE, SOLVD, CONSENSUS, V-HeFT, EMPHASIS-HF and SCD-HeFT, a lower stroke incidence has been . reported with annual stroke rates ranging from 1.1% to 4.6%.
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The incidence of ischaemic stroke in HF has been reported to be 18 per 1000 patients during the first year following HF diagnosis, which increases to 47 per 1000 patients at the end of 5 years.
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Notably, the risk of stroke is five-fold higher within the first 30 days after diagnosis of HF, becoming attenuated over time. 17 This was confirmed in a nationwide cohort study of the Danish population including 289 353 patients with HF and 1 446 765 individuals from the general population.
18 A five-fold increased rate of ischaemic stroke among HF patients and a two-fold increased rate of haemorrhagic stroke were observed within the first 30 days. Risk of stroke remained associated with HF during the following 30 years, 1.5-fold and 1.4-fold for ischaemic and haemorrhagic stroke, respectively. This long-term risk reduction may be related to treatment of the disease and initiation of stroke prevention measures.
A prognostic model has recently been proposed to predict the future risk of ischaemic stroke in HF patients based on eight readily obtainable clinical characteristics (age, gender, haemoglobin, blood urea nitrogen, ejection fraction, diastolic blood pressure, diabetes status, and prior stroke or transient ischaemic attack). 19 The risk increases with age, HF severity, and duration of HF. 20 In general, mild to moderate HF is associated with an annual stroke risk of approximately 1.5% compared to <0.5% in the general population while this increases to almost 4% in severe HF (supplementary material online, Table S3 ). 21 A stepwise increase of stroke risk was observed in parallel to increasing New York Heart Association (NYHA) classes and decreasing LV ejection fractions. 22 Patients with HF of ischaemic aetiology or with other co-morbidities including peripheral arterial disease, hypertension, valvular heart disease, diabetes, advanced obesity, prior stroke and an estimated glomerular filtration rate < 60 mL/min/1.73 m 2 have a higher stroke risk compared to HF patients who are free from these conditions. 23 Echocardiographic indicators provide inconsistent findings. The presence of slow flow patterns such as detection of spontaneous echo contrast, an enlarged left atrium, 24 LV dysfunction with apical akinesia or aneurysm are important factors to be considered as additional risk factors for intracardiac thrombosis and consequently of embolic stroke in patients with HF.
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Management of ischaemic stroke in heart failure
Patients with ischaemic stroke (∼85% of all strokes) should be treated in a stroke unit, using systemic thrombolysis (with rt-PA) and/or intra-arterial thrombectomy (if applicable) and later antiplatelet therapy. Patients with haemorrhagic stroke (∼15%) should also be treated in a stroke unit (or intensive care unit) by using antihypertensive and therapeutic strategies aiming to reduce increased intracranial pressure. Hemicraniectomy is employed only in rare cases and exceptional circumstances.
In theory, HF may reduce the benefit of thrombolysis by delaying distribution time of rt-PA, a higher chance of embolization of long-standing LV thrombi, as well as by causing or increasing hypoperfusion-related brain injury. However, a retrospective analysis of the non-randomized VISTA cohort showed a favourable effect of rt-PA on stroke outcome regardless of HF status. Rt-PA-associated risk of bleeding was nearly twice as high in stroke patients with HF [odds ratio 1.96 27 The effect of HF on the efficacy of mechanical recanalization after acute ischaemic stroke is not yet established. Only one randomized controlled trial reported that history of congestive HF was significantly associated with poorer baseline collateral grade and poor outcome after intra-arterial thrombectomy. 28 There are no published reports on the benefit of stroke unit treatment in HF patients with acute ischaemic stroke.
Prevention of ischaemic stroke in heart failure
While the beneficial effect of oral anticoagulation in HF patients with AF is well established, 13 there is no proven benefit of warfarin in patients with HFrEF and with maintained sinus rhythm because the reduced risk of thromboembolic events is outweighed by the about two-fold increased bleeding risk. The WARCEF trial showed a benefit of anticoagulation on the primary outcome (death, stroke, haemorrhage) only after 4 years of therapy. This benefit was offset, however, by a significantly increased risk of major bleeding. 29 In two meta-analyses, there was no significant difference in mortality between patients taking oral anticoagulation and those taking placebo.
30, 31 Rengo et al. 31 observed a benefit with warfarin over antiplatelet therapy in reducing the risk of stroke at the expense of an increased risk of major bleeding. Both the 2016 European Society of Cardiology guidelines 32 and a 2012 HFA joint consensus document 14 state that there is no compelling reason to use warfarin in HF patients with maintained sinus rhythm, given no overall benefit and increase in major bleeding. After stroke in HF patients with sinus rhythm, acetylsalicylic acid is the treatment of choice. Ongoing studies with novel oral anticoagulants (such as COMMANDER HF with rivaroxaban) 33 examine the role of anticoagulation in these patients.
Chronic low perfusion in patients with heart failure
Vascular auto-regulation (Bayliss effect) of the cerebral vascular bed enables maintenance of normal perfusion even with severely elevated blood pressure and protects the brain against blood pressure peaks. However, at low perfusion pressures, regional hypoperfusion may occur and chronic low perfusion may account for metabolic impairment, structural decrease and eventually functional decline of brain areas involved in autonomic, neuro-psychological, and cognitive control. 34 damage have been described in HF patients affecting autonomic (raphe, insula, cingulate, hypothalamus, ventral medial frontal cortex, and cerebellar areas), mood, and cognitive (cortex, hippocampus) regulatory areas. Regional vascular recruitment is modulated by functional activity and local oxygen demands and is locally controlled by a range of factors addressed as 'neuro-vascular unit', a heterogeneous structure composed of different cell types including astrocytes, pericytes, endothelial cells of the blood brain barrier, microglia, and neurons. 37 Regional hypoperfusion has been observed in HF in multiple brain areas being largely lateralized towards the right side in the occipital, temporal, frontal, and parietal regions. 38 Bilateral areas of reduced blood flow were observed in the prefrontal cortex, frontal white matter, anterior corpus callosum, thalamus, hippocampus, amygdala, and occipital cortex. The decreased regional perfusion may contribute to the autonomic, mood and cognitive regulatory deficits observed in HF. Further, impaired perfusion of multiple brain areas involved in control of vision, language and speech has been observed that could explain the respective deficits in HF patients.
Accelerated cognitive decline may result from chronic hypoperfusion in the long-term course of HF. Moreover, exacerbating episodes of severe cognitive impairment and delirium are commonly observed clinical observation in acute decompensated HF 39 and incomplete recovery during cardiovascular recompensation has been described. 40 
B. Higher cortical function Cognitive impairment in patients with heart failure
The prevalence of early-onset cognitive impairment ranges from 25% to 75% in patients with HF, 41, 42 being associated with early death, loss of functional independence, worse adherence to therapy and decreased quality of life. 43 Notably, according to the Swedish Heart Failure and Dementia Registries, the more common type of HF associated with dementia was HFpEF (defined as LV ejection fraction >40%): occurring in 38% compared to 34% of HFrEF. 44 Accelerated cognitive decline in executive function, attention, episodic memory, language, psychomotor speed, and viso-spatial ability are typical for HF patients, with differences between HFrEF and HFpEF. 45 -47 Possible pathophysiological mechanisms are associated with chronic cerebral hypoperfusion, microemboli from LV thrombi, disruptions of blood-brain barrier, vascular remodelling, systemic inflammation and endothelial dysfunction. Accordingly, injury and tissue loss of brain areas involved in cognition have been described such as in the frontal cortex, 48 hippocampus, 49 mammillary bodies, 50 and the putamen. 51 Clinical factors associated with cognitive decline and dementia in HF include a history of hypertension, stroke, AF, metabolic abnormalities, reduced ejection fraction and low cardiac output, impaired LV diastolic filling, high plasma brain natriuretic peptide, 52 reduced physical activity, depression, anaemia, liver failure, increased homocysteine, and low testosterone levels in males. 53 -55 The degree of cognitive impairment in HF ranges from delirium and dementia to isolated memory deficits. Defects in different cognitive domains have been described in HFrEF compared to HFpEF. 47 Two patterns of cognitive problems in HF are recognized in clinical practice: a chronic, progressive decline in cognitive ability and an acute change in cognition in association with decompensated HF. 39, 40 Delirium is a common sequela of decompensated HF and associated with prolonged in-hospital stay and increased mortality. Despite its high rate and severe clinical impact, the relationship between acute delirium and HF has not been studied in great detail. Structural brain damage, like brain atrophy, increased white matter hyperintensities, 56 grey matter loss 57 and silent cerebral infarction are frequently encountered imaging findings in HF patients with cognitive dysfunction. Reduced regional cortical thicknesses reflecting loss of neurons and glia has been observed in HF patients in cortical sites that control autonomic, cognitive, affective, language, and visual functions. 35 Axons and myelin are altered in HF, secondary to chronic and/or sub-acute ischaemic/hypoxic processes and these alterations would contribute to the multiple autonomic and neuropsychological symptoms found in HF. 36 58 Management of cognitive impairment in HF patients is poorly studied and further research is needed to investigate interventional concepts to improve self-care and outcomes. The ESC guidelines recommend appropriate treatment of HF and team working with dementia specialists.
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Depression and anxiety in patients with heart failure Depression in HF has become a major focus of research in recent years as the burden of HF continues to increase and many studies suggest poorer outcomes in HF patients reporting depression. 59 Co-morbid depression in HF is associated with poor quality of life, lower treatment adherence, greater morbidity and mortality, increased hospitalization and higher health care costs. 60, 61 Major depression is detected in 20-40% of patients with chronic HF and this is about four to five times higher than in the general population. 62 The prevalence of depression is higher in women than in men [32.7% (range 11-67%) vs. 26.1% (7-63%)]. 62 Higher prevalence rates have been linked to more severe functional class, and marked differences were observed between NYHA class II and III patients. Data reporting the prevalence of depression are variable because of the use of different assessment methods (validated questionnaires vs. clinical interviews, conservative vs. liberal cut-offs for depression diagnosis), and because of heterogeneity of cohorts. The plethora of depression symptom inventories is another cause of the heterogeneity.
Structural alterations leading to mood disorders in HF have been investigated in several clinical studies with cranial magnetic resonance imaging (MRI). Roy et al. 38 demonstrated that cerebral blood flow in HF patients was decreased in all sites of brain compared to controls. Brain mood regulating sites, e.g. the prefrontal cortex, cingulate, insula, hippocampus, amygdala, and cerebellar areas, were associated with reduced cerebral blood flow and injury in subjects with depression only. The majority of these areas displayed reduced cortical thickness. 35 They also showed that axonal changes in descending fibres of the medial forebrain bundle and hippocampus have significant roles in mediating hedonic behaviour, and increased axial diffusivity, indicating impaired axonal integrity, may contribute to depression and reduction in feelings of pleasure. 36 Autonomic regulatory sites like the hippocampus, thalamus, corona radiate and cerebellum were also affected from reduced cerebral blood flow and showed abnormal functional MRI signal responses to autonomic and cardiovascular challenges in HF. In a 24-month follow-up study of 19 participants with systolic HF and 45 controls, a relative loss of grey matter in brain regions modulating the emotions was positively correlated with increasing severity of anxiety and depressive symptoms. 63 Adverse effects of depression on cardiovascular diseases are believed to be mediated by shared pathophysiological mechanisms. Natriuretic peptides in HF have been shown to be altered in areas of the brain regulating blood pressure and fluid control in experimental animals. 64 Central natriuretic peptides show an antagonistic effect against the pressure and fluid neurotransmitters in HF and are associated with mental and emotional changes. 65 Drugs used for the treatment of HF may reverse these changes. 66 Depression may contribute to dysregulation of the autonomic system with reduction in the parasympathetic tone and increase in the sympathetic tone and its attendant increase in heart rate, reduction in heart rate variability and lower threshold for myocardial ischaemia and adverse cardiac events in patients with established cardiovascular diseases. 67 Other potential pathophysiological mechanisms include increased activity of the hypothalamic-pituitary-adrenal axis, and inflammatory cytokines [C-reactive protein, interleukin (IL)-6, IL-1 , and tumour necrosis factor-]. 68 Studies on novel biomarkers and neuroimaging are ongoing, but their therapeutic impact is yet unknown.
Although remission from depression may improve cardiovascular outcomes, effective interventional strategies are not yet known. Most of the antidepressant agents may safely be used in HF patients, but monoamine oxidase inhibitors and tricyclic antidepressants are usually avoided due to their unfavourable effects on blood pressure and pro-arrhythmic potential, respectively ( Table 3) . 69 Treatment of depression with antidepressants in HF has not been very encouraging and the results of two major randomized trials (SADHART-CHF 70 and MOOD-HF 65 ) did not show significant improvement in depression scores and HF outcomes with the use of selective serotonin re-uptake inhibitors. Short-term psychotherapeutic treatments like exercise training and cognitive behavioural therapy are safe and improve depression scores in meta-analyses of randomized controlled trials, but their sustainability in long-term clinical practice is unknown. 71, 72 Electroconvulsive therapy is considered to be safe, but cardiac complications (hypertension and arrhythmias) may occur even with a 'cardiac-modified' protocol. 73 Currently, the combination of cognitive behavioural therapy with a selective serotonin re-uptake inhibitor is the preferred management of depression in a HF patient. Despite the relevant co-morbidity of depression in HF, this condition remains frequently under-diagnosed and is rarely treated. More research is warranted to develop novel treatments targeted at depression in patients with HF.
Anxiety is another frequently encountered disorder in HF patients with a prevalence ranging between 9% to 53%. 74 Anxiety in HF is related to older age, low level of education, poor socioeconomic status, previous psychiatric disease, decreased quality of life, multiple hospitalizations, increased natriuretic peptide levels, and impaired functional capacity. 75 In a meta-analysis including six studies with 1-3 years of follow-up, anxiety did appear as an independent predictor of all-cause mortality (hazard ratio 1.02; 95% CI 1.00-1.04; P = 0.09) in HF patients. 74 Despite being less well studied in HF trials and neglected by most physicians, it may easily be assessed by using questionnaires like the Patient Health Questionnaire (PHQ), Hospital Anxiety and Depression Scale (HADS), PROMIS anxiety scales, Beck Anxiety Inventory (BAI), State-Trait Anxiety Inventory (STAI), Generalized Anxiety Disorder 7-item Scale (GAD-7). In observational small scale studies, effective management of HF-related symptoms improved anxiety scores significantly. 76 aerobic exercise seem to be as effective as drug therapy. 77 Repeated visits from nurses and routine contact calls from health care staff to give knowledge and care support were found to reduce hospital re-admissions and increase quality of life.
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C. Brain stem functionneuro-vegetative control
Neuro-cardiac reflex signalling in heart failure Imbalanced neuro-endocrine activation and control of the myocardium and circulation is understood as a cornerstone of HF pathophysiology and a driving force of disease progression and high mortality of HF. Consequently, autonomic nervous system abnormalities have been a recent and exciting therapeutic target in HF. 79 There are multiple cardiopulmonary reflexes that interact to keep blood pressure, heart rate, cardiac output, peripheral blood flow, fluid volume balance, ventilation, V/Q matching, arterial blood gases, and the metabolic state of the metabolizing tissues stable, even in illness, or during environmental or exertional stress ( Figure 2) . 80 Both peripheral and central chemoreflex changes are abnormal in HF. Peripheral receptors for baro-, metabo-, or chemosensitivity provide afferent signals to cerebral vegetative control centres that, in turn, trigger efferent sympathetic and parasympathetic signals to form baro-metabo, or chemoreflex circuits. The effect of disease on these individual reflexes has been studied to a limited extent, most notably for HF, diabetes and hypertension. Much less well studied is the interaction between two different disease states such as HF and its common co-morbidities, despite the importance of such features for conditions such as central sleep disordered breathing or HF with lung disease, cachexia, or diabetes. The interaction between reflex systems can be studied by looking at the integrated behaviour of cardiopulmonary reflexes using such techniques as power spectral analysis of heart rate, blood pressure and breathing rhythms. Studying isolated elements is complex and confusing, as there is much interaction and redundancy in the body's control systems. Although standard in physiological testing, the study of a single component of the autonomic nervous system by assessing its modification after an intervention of blockage or activation may be misleading. For example the effect of chronic sympathetic over-activity in HF cannot easily be derived from the short-term effects of beta-blockade in HF patients, as so many compensatory systems are at play. This has implications for our assessment of chronic actions of the chemoreflex, baroreflex, and central sympatho-vagal balance. Imaging studies of brain areas involved in autonomic regulation have shown distinct metabolic alterations 81 and abnormal functional response to autonomic challenges such as Valsalva manoeuvre 82 or cold pressure challenges. 83 Abnormal blood pressure, heart rate and breathing control, which derives from a reduction in baroreflex sensitivity and a concomitant increase in both peripheral and central chemosensitivity, leads to a classical pattern on reflex instability with a reduction in high and low frequency oscillations and a dominant very low frequency Are usually avoided due to their pro-arrhythmic potential and cardiac side effects like hypotension and worsening heart failure. Pharmacological agents for treatment of cognitive impairment Acetylcholinesterase inhibitors Cardiovascular adverse events occur rarely. The most frequently reported adverse effect is dysrhythmia in the form of bradycardia and conduction disorders. Syncope, oedema and hypertension maybe observed. Co-administration with beta-blockers, digoxin, amiodarone, and calcium channel blockers may increase the risk for syncope or heart block. Memantine Favourable side effect profile. Dizziness, hypertension, angina, bradycardia and heart failure may be observed.
MAOI, monoamine oxidase inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
oscillation, which in many cases (both in sleep and wakefulness) can manifest as frank Cheyne-Stokes respiration. This pattern is seen commonly in advanced HF and manifests as central sleep apnoea, such that HF is the most common cause of this type of sleep apnoea. The surprising finding of an unexpected increase in mortality in the SERVE-HF trial (see also below) has highlighted the importance of this mechanism in cardiovascular mortality when central sleep apnoea in HFrEF was treated with the AutoSet positive pressure airway mask. The putative mechanisms may be related to the adverse haemodynamic effects of positive airway pressure in a subset of 'sicker' HFrEF patients, although the exact mechanism remains uncertain. The impact of the central nervous system (CNS) on vegetative control of the cardiovascular system is poorly understood. One hypothesis that merits further investigation is the relationship between central command of the cortex and the activation of the respiratory centres located in the medulla. To date it has been shown that absolute measures of regional cerebral blood flow to the frontal cortex fail to rise in HF patients during exercise compared to the response in healthy controls. 84 It is also known that both time-domain and frequency-domain measures of heart rate variability are reduced in chronic HF and this very reduction is associated with increased mortality. It is tempting to suggest that reduced higher CNS function reduces its ability to deliver an intermittent 'kick' or perturbation to the brain stem pendulum, thereby detracting from the normal degree of variability. these components have been studied in isolation but we call for an integrated and comprehensive approach, since both lifestyle and pharmacological interventions that target the CNS may turn out to be the key to improved chronic HF survival. 85 Both ischaemic and haemorrhagic strokes can cause abnormalities in autonomic nervous system activity. Experimental and human studies have shown the association between stroke and increased levels of catecholamines and/or abnormal autonomic control of heart rate (heart rate variability and arterial baroreflex sensitivity) 86, 87 ( Figure 3) . Stroke-induced sympatho-vagal imbalance may affect the cardiovascular reflex systems through a number of different mechanisms. The activation of the sympathetic nervous system, especially upon injury involving the insular cortex, promotes the development of AF, ventricular arrhythmias, endothelium dysfunction, and abnormalities in QT interval. 88, 89 Baroreflex dysfunction may cause hypertensive crises and a high variability of blood pressure, often resistant to therapy, in the early post-stroke period and in more severe HF can lead to persistently low blood pressure and poor stabilization of perfusion pressures. Finally, in myocardial cells it can reduce myocardial contractility and induce myocardial cytolysis. The myocardial injury, subsequent to sympathetic over-activity, can lead to the release of cardiac enzymes. In patients with an ischaemic stroke, the prevalence of troponin elevation varies between 18% to 60% depending on the sensitivity of the assay and number of serial measurements. 90 The increase of troponin serum levels has been generally associated with increased mortality. 90, 91 Although elevated troponins are the most sensitive marker to indicate acute myocardial injury, HF and renal dysfunction can as well cause (chronic) elevation of troponins. Dynamic increase of troponin may indicate the presence of an acute coronary syndrome 90 but interpretation may be difficult in a number of conditions including stroke. 92, 93 Notably, involvement of insular cortex in stroke is frequently associated with increased troponin levels during the first days of ictus. More specifically, a dynamic change of this biomarker was commonly observed in the involvement of right insula. 94 Decision for or against intensified acute coronary diagnostics based on elevated troponin levels with pre-existing coronary artery disease co-morbidity is a regular question at stroke units. Evidence for appropriate interpretation of troponin levels in the setting of stroke is warranted.
The Takotsubo syndrome (TTS) probably shares a neurogenic origin with the stress-related cardiomyopathy observed in stroke. However, in patients with stroke, there is a different distribution of wall motion abnormalities, generally sparing the apex, whereas in TTS apical and mid-ventricular wall motion abnormalities predominate. 95 Although 'apical ballooning' describes the typical phenotype of transient LV contractile impairment, several other variants of regional contractile impairment have been observed. A wide range of factors related to metal or physical stress is known as potential trigger for TTS leading to neuroendocrine overflow and myocardial stunning. Recent data suggest that 1-2% of patients with suspected acute coronary syndrome are eventually diagnosed with TTS. It affects predominantly (>90%) females and particularly elderly patients (<10% of patients are below 50 years . 
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TTS was primarily considered an acute HF syndrome with a benign prognosis. Recent evidence suggests, however, much higher mortality rates with long-term mortality similar to patients with non-ST and ST-elevation myocardial infarction due to severe complications including HF, cardiogenic shock, or life-threatening arrhythmias. 97, 98 
D. Interactions related to heart failure treatment
Patients with HF are usually older adults with several associated disorders influencing pharmacokinetics and pharmacodynamics of drugs. Prevalent co-morbidities, physiological and pathophysiological changes in the cardiovascular system with ageing, and with HF itself, result in distinct effects of common cardiac problems as well as the response to therapy. Clinical HF trials enrolling elderly patients are limited. Recommendations are often derived from studies in younger people and hence are lacking evidence in patients aged >75 years. Age-and HF-related alterations in body weight, lipid and water compartments, sarcopenia, decline in renal and hepatic function, and drug interactions due to polypharmacy may affect the expected beneficial effects of guideline-directed medical therapies. The interactions and possible side effects of contemporary HF therapies on neuropsychiatric status of HF patients are summarized in Figure 3 Cerebro-cardiac signalling after stroke. BP, blood pressure; HF, heart failure.
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers and mineralocorticoid receptor antagonists
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have been shown to improve cognitive function when used as antihypertensive agents, independent of their effects on blood pressure, and are superior to beta-blockers and diuretics. 99 ACE inhibitors were also shown to reduce the occurrence of vascular dementia following haemorrhagic or ischaemic cerebrovascular accidents. 100 In contrast to these findings, Khachaturian et al. 101 reported that ACE inhibitors were the only antihypertensive drugs to show a slightly increased incidence of Alzheimer's disease. Zuccalà et al. 102 reported that ACE inhibitors selectively improved cognitive performance in patients with HF, when the target doses were achieved. The cerebrovascular benefits of ARBs seem to be class-related and all ARBs might be used in primary stroke prevention. 103 The prevention of stroke recurrence should not be considered a compelling indication for treatment with ACE inhibitors. Table 4 . Theoretically, ACE inhibitors and ARBs may cause weakness, dizziness, or syncope due to excessive blood pressure reduction after administration. Systolic blood pressure levels below 130 mmHg are associated with an increased probability of cognitive impairment among hospitalized patients with HF who received vasodilator agents.
Side effects of HF treatments are summarized in
105 Particular attention should be paid to very elderly patients who are more prone to side effects of blood pressure lowering and subsequent cerebral hypoperfusion leading to cognitive decline, falls, and depression. The risk can be minimized by beginning with low doses and careful up-titration to the maximum tolerated dose in patients with HF.
Beta-blockers may also lead to dizziness and hypotension in HF. In a meta-analysis including 13 796 patients, beta-blockers were associated with a 41% relative increase in risk of hypotension (relative risk 1.41; 95% CI 0.96-2.06). 106 The absolute annual increase in risk was 11 per 1000 patients (95% CI 0-22), equal to 91 patients treated for 1 year to cause one additional report.
In another analysis of two randomized controlled trials including 2193 patients, no available evidence supported the routine use of beta-blockers for secondary prevention after stroke or transient ACE, angiotensin-converting enzyme; AF, atrial fibrillation; AFl, atrial flatter; ASD, atrial septal defect; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; HF, heart failure; HTx, heart transplantation; ICD, implantable cardioverter-defibrillator; LVAD, left ventricular assist device; MRA, mineralocorticoid receptor antagonist; PCI, percutaneous coronary intervention; PFO, patent foramen ovale; PTSD, posttraumatic stress disorder; VA-ECMO, veno-arterial extracorporeal membrane oxygenation.
ischaemic attack. 107 Additionally, clinicians need to take into consideration the potential negative impact that beta-blockers may have on cognition when determining the best treatment of hypertension among older adults. 108 On the other hand, irrespective of age or sex, patients with HFrEF in sinus rhythm should receive beta-blockers to reduce the risk of death and admission to hospital according to the results of a meta-analysis of 13 833 patients with LV ejection fraction <45% from 11 trials.
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Mineralocorticoid receptor antagonists did not change the incidence of stroke, nervous system or psychiatric disorders in RALES and EPHESUS trials. The brain mineralocorticoid receptors mediate the actions of corticosteroids in patients with stress and depression, however the role of mineralocorticoid receptor antagonists in depression are controversial and more studies are required to thoroughly elucidate their role in the management of these patients.
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Novel agents
Sacubitril/valsartan (formerly labelled as LCZ696) is a novel agent combining the angiotensin receptor antagonist valsartan with sacubitril, which is a neprilysin (NEP) inhibitor, thus forming a new class of HF treatment, ARNI. In the PARADIGM-HF trial, hypotension was more frequent in patients randomized to LCZ696 compared to patients randomized to enalapril. 111 An unresolved concern about sacubitril/valsartan is its potential risk . of promoting Alzheimer's disease. 112 The main pathological feature of Alzheimer's disease is the production of a 40-42 amino acid peptide called amyloid beta (A ), which is the building brick for A protein accumulation and deposition in the brain, e.g. as extracellular senile plaques or within the walls of the cerebrovasculature. NEP is a cell-surface zinc metallopeptidase, which is one of the enzymes in the brain capable of degrading A . Hence, a theoretical risk of NEP inhibition relates to effects on A metabolism, and the accumulation of A in the brain. Elevated levels of A were present in cerebrospinal fluid and plasma but not in brain samples of cynomolgus monkeys treated with sacubitril/valsartan for 2 weeks at a clinically relevant dose. 113 This suggests that the newly synthesized A was eliminated from brain tissue by other (non-NEP) clearance pathways. 114 Analyses of PARADIGM-HF study did not point to an increased risk of dementia or Alzheimer's disease in these patients. 115 However, further research is ongoing to investigate potential effects of long-term exposure to sacubitril/valsartan on cognitive function.
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Exercise
The beneficial effect of exercise to improve functional status and outcome in patients with HF may result from a range of mechanisms, including indirect effects via cerebral signals such as improved sympatho-vagal balance and attenuated activation of ergo-and metabo-reflexes, 117 enhancing cerebral haemodynamics, 118 and even via cortical, antidepressive effects of exercise.
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Device therapy
Patients receiving a device therapy generally show an increase in depressive symptoms and anxiety during the initial months after implantation. The risk of mood disorder is increased by type D personality, concerns on implantable cardioverter-defibrillator (ICD) therapy, diabetes, NYHA class III-IV, receiving psychotropic medication, and younger age.
119 Especially in patients with favourable response to device (e.g. cardiac resynchronization) therapy, these symptoms fade and cognitive performance improves in the following months. Nevertheless, receiving either an appropriate or inappropriate ICD shock leads to emotional dysfunction, anxiety and depression during the month following the shock. Almost 20% of patients with ICD suffer from posttraumatic stress disorder due to a history of cardiac arrest, device implantation, and ICD shock, and it seems cognitive and behavioural therapy can potentially improve outcomes.
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A range of new devices and procedures are being evaluated for potential prognostic and/or symptomatic benefit such as intracardiac pacemakers, catheter ablation of AF, transcatheter aortic valves, and phrenic nerve or carotid stimulation that could as well be a 'trigger' for brain injury. Longer clinical experience is warranted to see their impact on heart and brain interaction.
Sleep apnoea is a frequent co-morbidity in patients with HF. Central sleep apnoea in particular is driven by abnormal regulation of the respiratory centres in the brain stem through increased afferent chemosensitivity and excess sympathetic nervous activity. The effect of improved tissue oxygenation by adaptive servo-ventilation in patients with moderate to severe HF and LV ejection fraction ≤45% had been tested in the SERVE-HF study.
121 Unexpectedly, an increased total and cardiovascular mortality was observed with augmented ventilation rendering this therapy unsuitable for patients with HFrEF and central sleep apnoea. 122 The mechanisms to explain the increased mortality remain until now largely unexplained. However, the failure of mere ventilator support to translate into prognostic benefit in these patients underscores the importance of better understanding of neuro-vegetative reflexes in the control of cardiovascular function.
Revascularization
Revascularization with coronary artery bypass grafting carries a considerable risk for ischaemic stroke due to cerebral embolization of atheromatous debris arising from the ascending aorta and due to hypoperfusion during surgery.
123 Stroke after coronary artery bypass grafting is associated with prior neurological events, aortic atherosclerosis and duration of surgery. Delayed stroke is not only related to prior neurological events and aortic atherosclerosis, but also to diabetes, AF and low cardiac output. Female sex is associated with a 6.9-fold risk of early stroke and a 1.7-fold increased risk of delayed stroke. of the patients and account for 34% of all deaths in patients after LVAD implantation. 124 LVAD-induced changes in systemic immunologic function and coagulation cascade (associated with platelet dysfunction and acquired von Willebrand syndrome) might potentially lead both to thrombotic cerebral infarction and haemorrhage. The risk of bleeding is greater than that of thromboembolism. Common postoperative LVAD complications include low pump flow, right ventricular dysfunction, bleeding, dysrhythmias, infection, device malfunction and thrombosis, secondary organ dysfunction, and associated neurocognitive changes. 125 Female sex and age ≤ 65 years were risk factors for haemorrhagic stroke, whereas female gender and diabetes were risks for ischaemic stroke. Intraoperative echocardiography is essential for identifying valvular pathology, intracardiac thrombi, and an atrial septal defect or patent foramen ovale. Intracardiac thrombus should be removed before LVAD implantation and patent foramen ovale should be closed at the time of implantation. Close monitoring of LVAD parameters, anticoagulation, blood pressure, cholesterol and wound healing are important strategies for minimizing stroke risk.
Mechanical circulatory support and heart transplantation
Limited data are available on the effects of long-term support with LVAD on cognitive function. A recent study in patients with end-stage HF demonstrated that haemodynamics and cognitive function improved significantly at 8 months after LVAD implantation, suggesting that improvement in cardiac output and cerebral perfusion may have a beneficial impact on cognitive function.
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Studies have shown that improvement of cognitive function with LVAD is independent of the mode of flow support (pulsatile vs. continuous). 127, 128 In a multicentre, observational registry (INTERMACS) including 4419 patients who underwent LVAD implantation, cognitive function was assessed in 1173 patients before LVAD and at 3, 6 and 12 months. The study detected several forms of cognitive impairment, including sub-clinical stroke.
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This study highlighted the heterogeneity of LVAD treatment effects on cognition, where some patients clearly improve and others decline. Cognitive deterioration occurred commonly in the year after LVAD and was associated with older age and destination therapy. Therefore, it is critical to assess the cognitive function before the implementation of LVADs.
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is an established strategy for cardiopulmonary support in patients with cardiovascular collapse. Its common complications are thrombosis, bleeding, coagulopathy, limb ischaemia, infection, and stroke (10-33%). Heart transplantation improves cognitive performance by increasing cerebral blood flow.
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E. Specific diseases linking heart failure and the brain
A range of diseases account for myocardial damage as well as cerebral injury. The detailed discussion of these pathologies is beyond the scope of this paper. Aiming, however, for a systematic classification of heart and brain interaction relating to HF, a separate category is proposed. This category includes specific diseases of non-cardiac origin that contribute to the development of cardiomyopathies and HF and account in parallel for disease-specific cerebral injury and neurologic symptoms. Examples for specific diseases linking development or progression of HF with cerebral interaction are shown in Table 5 .
Unresolved issues and gaps in evidence
A range of interactive signals between heart and brain are well established to result from injury in one organ affecting the functional status of the other. However, much of the complex interaction between both organs is yet to be uncovered. More studies on individual aspects and embedded in a systematic concept are needed to address the mutual aggravation of functional interference that contributes to both symptomatic presentations and progression of HF. This paper, by categorizing the multiple links between myocardium and the brain, aims to provide a structured approach to systematically investigate these interactions. Better pathophysiological insights are very important to promote novel therapeutic concepts towards both HF progression as well as cerebral complications such as cognitive decline, depression, neuro-vegetative impairment, or stroke.
A. Impaired cerebral perfusion Stroke and heart failure
The prevalence of acute coronary syndromes associated with stroke is unknown. Available evidence for clinical signs, imaging and biomarkers of myocardial injury is inconsistent and demands further investigation. In turn, prospective studies are needed to investigate whether early detection of high-risk patients and optimal treatment with anticoagulation may reduce the incidence of stroke in HF patients. 
B. Higher cortical function Cognitive impairment and heart failure
The role of cerebral hypoperfusion or silent cerebrovascular ischaemia in vascular dementia should be described more clearly. Mechanisms such as involvement of pericyte regulation within neurovascular unit control of capillary recruitment need to be investigated. Specific guidance on treatment of cognitive impairment in HF is needed. Cognitive dysfunction in association with contemporary HF medications is not well studied (it is the exclusion criterion in almost all of the phase 2 and 3 HF trials) and results of small studies and molecular back-up mechanisms are controversial.
Depression and heart failure
Standardized best practice for screening and diagnosis of depression in HF has not been consolidated among experts from involved specialties. Indeed, it is crucial to establish uniformity for research and to standardize the exact prevalence. The causal relationship between depression and HF needs further evaluation. Best treatment modality is unknown (drugs or psychotherapy). In the presence of failed therapies in clinical trials, it might be crucial to identify potentially existing phenotypes of depression that might or might not benefit from antidepressant therapy.
C. Brain stem function
Neuro-endocrine signalling in heart failure and stroke Few data are available about the relationship between stroke, troponin increase, myocardial injury, and the occurrence or worsening of HF. It is not clear if autonomic dysfunction in stroke could represent a therapeutic target. Studies on the effect of beta-blockers on sympathetic over-activity and prognosis are conflicting.
The relationship between stroke and the occurrence of TTS or neurogenic stress cardiomyopathy should be better clarified. The long-term independent prognostic role of stress-related myocardial injury associated with high troponin levels, the prevalence and phenotype of stress-related cardiomyopathy, and therapeutic options need further and larger studies. In addition in TTS there may also be a direct interaction with abnormal autonomic function and abnormal LV physiological responses. Clonidine, moxonidine and mecobalamin may play a role in improving baroreflex function and reducing pressure variability, but the evidence about their usefulness is insufficient. The role of elevated natriuretic peptides and other neuropeptides in cerebral perfusion in patients with acute and chronic HF is incompletely understood.
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D. Medical and device therapy interfering with cerebral function
Continued work is needed to clarify the side effect profile of HF medical therapy on cognitive and other cerebral functions and to establish the impact of novel treatments such as sacubitril/valsartan.
E. Disease-specific interactions
The exact role of parasympathetic impairment, neurogenic stress cardiomyopathy, pro-inflammatory cytokines in ischaemia, fibrosis, and the effect of anticoagulation in the context of numerous specific diseases need further research. Further diseases and co-morbidities of HF with myocardial-cerebral interactions may and should be addressed in this section including but not limited to diabetic polyneuropathy, sleep disordered breathing, Friedreich ataxia, storage diseases such as Fabry disease or amyloidosis.
Conclusions
Heart failure is a complex clinical syndrome with multiple interactions between the failing myocardium and the brain. These bi-directional interactions are inherent pathophysiological features of HF. They contribute to symptomatic presentation of HF patients and account for relevant co-morbidities such as stroke, sleep apnoea, cognitive impairment, or depression. Neuro-cardiac feedback signals significantly promote further progression of HF and are causal for a poor prognosis. A better understanding of the complexity and diversity of heart and brain interactions is warranted to improve management and prognosis of HF patients. A systematic approach to categorize these multiple interactions is proposed in this paper. Such a methodical concept may be helpful to develop an integrated overall picture and build a comprehensive atlas of heart . . 
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